Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Cash from Financing Activities came in at $19.1 million in Q1 2026, up 288.08% year-on-year from $4.9 million in Q1 2025, and up 3619.93% on a QoQ basis from -$542000.0 in Q4 2025.
Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Cash from Financing Activities data on file, last reported at $19.1 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 288.08% year-over-year to $19.1 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 441.3% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 119.87% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $19.1 million, up from -$542000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for GLAS reached as high as $8421.8 billion in Q3 2023 and fell as low as -$779.1 billion in Q4 2022.
- Historically, Cash from Financing Activities has averaged $449.6 billion across 5 years, with a median of $551000.0 in 2023.
- Across the five-year window, Cash from Financing Activities jumped 100895742.82% in 2023 and sank 784.03% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at -$779.1 billion in 2022, then jumped by 100.0% to $551000.0 in 2023, then sank by 784.03% to -$3.8 million in 2024, then jumped by 85.62% to -$542000.0 in 2025, then surged by 3619.93% to $19.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $19.1 million in Q1 2026, -$542000.0 in Q4 2025, and $231000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -1.48 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 19.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.08 Mn |
| Mar 31, 2026 | 19.08 Mn |
| Dec 31, 2025 | -542,000.00 |
| Dec 31, 2025 | -542,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | 551,000.00 |
| Dec 31, 2023 | 551,000.00 |